Genentech, FDA Discussing Herceptin Label Changes To Reflect New PK Data
Executive Summary
Genentech and FDA are discussing updates to Herceptin labeling following the submission of preliminary data suggesting the half-life of trastuzumab is up to five times longer than previously thought.